Chronic Lymphocytic Leukemia, 1st ed. 2019
Hematologic Malignancies Series

This book summarizes current knowledge on chronic lymphocytic leukemia (CLL), taking into account the most recent research. All aspects are considered, including pathophysiology, clinical presentation, diagnosis, prognosis, treatment, follow-up, and complications and their management. Readers will find important information on the various prognostic markers as well as practical guidance on the use of different diagnostic procedures. A key focus of the book is the changing treatment paradigm in CLL as progress in understanding of pathogenesis and pathophysiology leads to the identification of new potential therapeutic targets. General treatment concepts are clearly described, and it is explained how choice of treatment for CLL depends on stage, age, and performance status as well as specific genetic aberrations. In addition, frontline therapeutic strategies for disease relapse, including allogeneic stem cell transplantation, are reported. Looking beyond CLL, the diagnosis and therapy of T-cell prolymphocytic leukemia and T-cell large granular lymphocyte leukemia, two rare CLL-related entities, are addressed.

Michael Hallek, MD, received his medical degree from the University of Munich, Germany, in 1985. From 1985 to 1990, he trained in pharmacology and internal medicine at that university and at the Technical University of Munich. He then spent two years as a research associate at the Dana Farber Cancer Institute at Harvard Medical School, Boston, USA, before returning to the University of Munich, where he continued his training in internal medicine and in hematology and oncology. From 1994 to 2005, he was head of the Gene Therapy Program at the Gene Center of the University of Munich and at the National Center for Research on Environment and Health (GSF), Munich. In 1994, he founded the German CLL Study Group (DCLLSG) and has remained its chairman until today. Since 2003, Dr. Hallek has been Professor of Medicine, Director, and Chair of the Department I of Internal Medicine at the University of Cologne. Since 2007, he has also been chairman of the Center for Integrated Oncology (CIO), the joint comprehensive cancer center of the Universities of Cologne and Bonn. In 2011, he became a member of the National Academy of Sciences (Leopoldina). Besides numerous awards, he has received the honour of the Ham-Wasserman Lecture during the American Society of Hematology in 2018. Since 2018, he has been chairman of the scientific committee of the European School of Haematology, Paris.

Barbara Eichhorst, MD, PhD, graduated from the Medical School of the University of Munich in 1997. She did her doctoral thesis in the field of hematology, evaluating signaling transduction pathways in Hodgkin cells. Dr. Eichhorst completed an internship at the Department III for Internal Medicine at Klinikum Großhadern of the University of Munich before becoming a consultant for internal medicine. She has worked at the University Hospital of Cologne since February 2005 and was appointed a consultant in hematology and internal oncology there in April 2006. She becam

Summarizes current knowledge on all aspects of CLL

Describes the role of different diagnostic procedures

Examines the changing treatment paradigm in CLL and the emergence of new therapeutic targets

Equips readers to make the most appropriate treatment choice in individual patients